2075. The Hypothetical Impact of Accelerate Pheno on Time to Appropriate Therapy (TTAT) and Time to Optimal Therapy (TTOT) in an Institution with an Established Antimicrobial Stewardship Program & Rapid Genotypic Organism/Resistance Marker Identification.
Session: Poster Abstract Session: Diagnostics: Resistance Testing
Saturday, October 6, 2018
Room: S Poster Hall
Background:

Rapid organism identification (ID) & antimicrobial susceptibility testing (AST) can improve time to adequate therapy (TTAT) and optimal (TTOT). The Accelerate PhenoTM system (ACC) can provide ID & AST results within 7 hours. The objective of this study was to assess the hypothetical impact of ACC on TTAT and TTOT in a hospital with an established antimicrobial stewardship program & rapid genotypic organism and resistance marker ID.

Methods:

Patients with positive blood cultures, at the Detroit Medical Center, from 3/29/2016 – 6/14/2016, were retrospectively reviewed. ACC was run on unique blood cultures as part of the laboratory validation of the system. ACC results were not made available to clinicians. These results were utilized to determine the hypothetical impact on TTAT and TTOT that the ACC results would have had in real time. This assessment was performed based on how clinicians modified antimicrobial therapy with regards to antibiotic choice and timing, once ID or AST were known. The assumption was that the same decisions that were made at the time of traditional AST would have been made when ACC information would have been available. In addition, the impact of ACC on total antimicrobial usage was assessed.

Results:

The analysis included 148 patients. The median actual TTAT was 2.2 hours (h) [interquartile range (IQR) 0.5 - 12.5 h]. If ACC results had been available, TTAT could have been improved in 11 patients (7%), with a median potential decrease in the TTAT of 2.3 h [IQR, 0.8 - 20.7]. The median actual TTOT was 40.7 h [IQR, 21.3 - 74.1]. If ACC results were available, improved TTOT could have been achieved in 59 patients (40%), with a median potential decrease in TTOT of 24.2 h [IQR 15.3 - 34.9]. The TTOT would have been achieved by earlier de-escalation in 53/59 (89.8%) patients. ACC implementation could have led to decreases in antibiotic usage for cefepime (17% reduction of actual use), aminoglycosides (23%), piperacillin/tazobactam (8%), and vancomycin (5%).

Conclusion:

Given the aggressive nature of empiric therapy and the availability of other rapid diagnostic tests at our center, ACC would have had a minimal impact TTAT. However, largely due to the ability to more rapidly de-escalate, ACC could have led to a more rapid TTOT in 40% of patients, and significantly reduced the use of broad spectrum antimicrobials.

Christopher Cooper, MD1, Oryan Henig, MD2, Keith Kaye, MD, MPH2, Noman Hussain, MD3, Zara Hussain, MBBS4, Kathryn Deeds, BS5, Hossein Salimnia, Ph.D.4,5, Paul Lephart, Ph.D.2, Umar Hayat, MD4, Jinit Patel, MD4 and Jason M. Pogue, PharmD, BCPS-AQ ID4,5, (1)Michigan State University, East Lansing, MI, (2)University of Michigan Medical School, Ann Arbor, MI, (3)Henry Ford Health System, Detroit, MI, (4)Detroit Medical Center, Detroit, MI, (5)Wayne State University, Detroit, MI

Disclosures:

C. Cooper, None

O. Henig, None

K. Kaye, Zavante Therapeutics, Inc.: Scientific Advisor , Consulting fee .

N. Hussain, None

Z. Hussain, None

K. Deeds, None

H. Salimnia, None

P. Lephart, None

U. Hayat, None

J. Patel, None

J. M. Pogue, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.